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In the process of biological genetic information transmission, complete 
and correct genetic information can make cell mitosis proceed normally. 
In the development of most tumor cells, G2/M cell cycle checkpoint be-
comes the key checkpoint in the process of mitosis due to the lack of G1/
S cell cycle checkpoint, which mainly depends on the abnormal DNA in-
formation blocked by Wee1 protein kinase in G2 phase to enter M phase 
and prolong the time of G2 phase to complete DNA sequencing So that 
the normal genetic information can be passed on. Wee1 protein kinase 
expression is significantly increased in most tumor cells, making it a po-









Yantai Yuhuangding Hospital, No. 20 Yuhuangding East Road, Zhifu District, Yantai, Shandong, 264000, China;
Email: ygh0536@163.com 
1. Introduction
Wee1 protein kinase family includes Wee1A, Wee1B 
and Myt1 members [1]. The human Wee1 gene is located 
in the P15 region of chromosome 15 [2] (11p15.3-11p15.1), 
encoding 647 amino acids. Wee1 protein kinase consists 
of three domains: N-terminal domain, central kinase do-
main and C-terminal regulatory domain [3]. The N-terminal 
domain is the activation domain of Wee1 protein kinase, 
which plays a key role in guiding its destruction, and may 
inhibit the activity of Wee1 protein kinase [4]. However, 
the N-terminal domain is also a potential site for inhibit-
ing CyCB/CDK1 dephosphorylation, thus causing cell cy-
cle arrest. The central kinase domain is helpful for Wee1 
localization in the nucleus at G2 phase; The C-terminal 
regulatory domain is the Wee1 protein kinase catalytic 
domain [5]. Studies have shown that Wee1 is mainly ex-
pressed in the nucleus of tumor cells [6]. In recent years, 
the research of Wee1 protein kinase in DNA repair of cell 
cycle damage and malignant tumors has become a hot 
spot. In normal cells, due to the existence of P53, cells 
can complete the damage repair in G1/S phase when DNA 
is damaged. However, the mutation of P53 occurs in most 
malignant tumors, resulting in that the damaged DNA can 
not be repaired in G1/S phase, and can only be repaired in 
G2/M phase [7], so that the correct and complete DNA can 
enter into M phase for mitosis. In this paper, the research 
progress of the relationship between Wee1 and tumor gen-
esis and development is summarized as follows.
2. Role of Wee1 Protein Kinase in Cell Cycle
Cell cycle is a concept proposed by Howard et al in 
1951. It refers to the whole process of a cell from the 
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completion of one division to the end of the next divi-
sion, which is divided into two stages: interphase and 
division phase. The interphase is divided into G1, S and 
G2 phases, and the division phase is M phase. In the 
process of cell proliferation, cell mitosis will encounter 
a variety of damage factors causing DNA damage and 
chromosome variation, so someone put forward the con-
cept of cell cycle checkpoint, namely a kind of negative 
feedback regulation mechanism, which is mainly affect-
ed by DNA replication and damage. There are two key 
checkpoints: G1/S and G2/M phases,which block the 
heredity of genes with replication errors. In normal cells, 
DNA damage mainly depends on two pathways mediated 
by P53(tumor suppressor gene): ATM(Capillary ataxia 
mutant gene)/ATR-P53-CDK4/CyclinD or ATM/ATR-
P53-CDK2/CyclinE inhibit Rb phosphorylation, and 
make the cell arrest in the G1 phase to complete DNA 
damage repair. However, studies have shown that most 
tumor cells lack two pathways in the G1/S phase check-
point, which makes the DNA damage repair of tumor 
cells mainly depend on the G2/M phase. Studies have 
shown that [7] Wee1 and CDC25 play an important role 
in this checkpoint. ATM/ATR is activated when DNA 
damage [8], through the phosphorylation of downstream 
CHK1/2(effect kinase) make its activation [9]. On the one 
hand, activated CHK1 / 2 can phosphorylate downstream 
CDC25B/C to inactivate it, inhibit its dephosphorylation 
of downstream CDK1/CycB, and arrest cell cycle in G2 
phase. On the other hand, CHK1/2 can directly activate 
Wee1 protein kinase. The activated Wee1 protein kinase 
phosphorylates the thy15 site of CDK1 [10] and inac-
tivates it, which is the key factor for mitosis. The cell 
cycle is arrested in G2 phase until DNA damage repair is 
completed. The cell has the opportunity to enter M phase 
for mitosis. Wee1 protein kinase, as a potential molecu-
lar target of tumor cells, has become a focus of current 
research.
As shown in Figure 1：
Figure 1. damage and repair process of G2 phase cells
3. Relationship between Wee1 Protein Kinase 
and Tumor
3.1 Wee1 and Gastric Cancer
Gastric cancer is one of the most common malignant 
tumors in China. Many chemotherapy drugs can cause 
DNA damage in gastric cancer tumor cells. Tumor cells 
lack G1/S phase and most of them rely on G2 phase ar-
rest. Wee1 is a key factor of G2/M checkpoint. Kim et al. 
[11] first proposed that Wee1 protein kinase might be ex-
pressed in gastric cancer. After a series of experiments, 
it was found that Wee1 was positive in gastric cancer 
cells, and the positive rate was higher in tumor cells with 
lymph node metastasis, and the proliferation and inva-
sion ability of tumor cells with Wee1 overexpression was 
stronger. Zhang et al. [12] also verified that the expression 
of Wee1 was increased in gastric cancer cells, and fur-
ther demonstrated that ROP inhibited the proliferation 
and metastasis of gastric cancer cells by regulating the 
Wee1 pathway.
3.2 Wee1 and Melanoma
In malignant melanoma, regardless of the status of 
P53, the high expression of Wee1 can reduce the DNA 
damage of tumor cells, and is positively correlated 
with the proliferation, metastasis and poor prognosis of 
malignant melanoma [13]. Studies have shown that [14], 
different from most tumors, P53 expression is positive 
in malignant melanoma. Wee1 is a key signal molecule 
downstream of BRAF in MAPK signal transduction 
pathway. Wee1 can inhibit the P53-P21-CDK2/CycE-
Rb-E2F pathway in the cell cycle, so that the cell cycle 
is blocked in the S phase, therefore, the expression of 
Wee1 protein kinase is still positive in melanoma. Wee1, 
as the most suitable target, its inhibitor and AKT3 pro-
tein kinase inhibitor combined to treat melanoma, so that 
the treatment effect of AKT3 inhibitor is more effective. 
In animal experiments, high expression of Wee1 and de-
letion of MicroRNA-155 (MiR-155) contribute to metas-
tasis of malignant melanoma [15]. However, Bhattacharya 
et al. [16] showed that compared with primary melanoma, 
the expression of Wee1 in distant skin metastatic mela-
noma was down regulated, and the proliferation, migra-
tion and invasion ability of Wee1 positive primary tumor 
cells were decreased.
3.3 Wee1 and Colorectal Cancer
Wee1 can be expressed in both colon cancer tissues 
and paracancerous normal tissues, but it is highly ex-
pressed in colorectal cancer [17]. Experiments showed 
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that the expression of Wee1 is mainly positive in the 
nucleus, but also slightly expressed in the cytoplasm, 
and the high expression of Wee1 is closely related to 
distant metastasis of colon cancer, lymph node metas-
tasis and malignant degree of tumor [18]. Yin et al. [19] 
verified that Wee1 inhibition can reduce the prolifer-
ation ability of tumor cells in P53 mutated colorectal 
cancer, and Wee1 may become a potential target for the 
treatment of colorectal cancer. Webster et al. [20] also 
found that the positive expression rate of Wee1 was 
up-regulated in endothelial cells with liver metastasis 
from colorectal cancer, and Wee1 may be related to the 
formation of some branches of blood vessels in liver 
metastasis from colorectal cancer, which provides a 
theoretical basis for the research and development of 
Wee1 protein kinase inhibitors as tumor drugs.
3.4 Wee1 and Breast Cancer
Triple Negative Breast Cancers (TNBCs) are breast 
cancers that are negative for estrogen receptors, pro-
gesterone receptors and human epidermal growth factor 
receptors. Studies have found [21] that p53 mutations in 
the vast majority of TNBCs lead to deletion of G1/S 
stage checkpoints, making Triple Negative Breast Can-
cer dependent on G2/M stage checkpoints to repair DNA 
damage. Experimental results showed [22] that Wee1 in-
hibitor combined with ATR inhibitor can inhibit prolifer-
ation and metastasis of TNBCs and induce apoptosis of 
cancer cells. Ghiasi et al. [23] eliminated G2 phase arrest, 
accumulated P53, increased G1 phase arrest and sig-
nificantly reduced the expression of pro-tumor vascular 
growth factor VEGF by inhibiting Wee1, thus weakening 
the proliferation ability of cancer cells, indicating the 
cancer-promoting effect of high expression of Wee1 in 
breast cancer cells.
3.5 Wee1 and Lung Cancer
Yoshida et al. [24] analyzed 79 patients by immuno-
histochemistry, including 16 recurrent cases, and found 
that there was almost no difference in the positive rate of 
Wee1 between tumor cells and normal cells. Moreover, 
the recurrence rate and mortality of patients with Non-
Small Cell Carcinoma(NSCLC) with negative Wee1 
expression were significantly higher than those with 
positive Wee1 expression.These results suggest that 
Wee1 expression may act as a protective mechanism 
against cancer in NSCLC. However, Ku et al. [25] proved 
that Wee1 protein kinase inhibitor was effective in the 
treatment of non-small cell lung cancer with KARs 
gene mutation in TP53 mutated cancer cells, which was 
similar to the effect of Wee1 inhibitor combined with 
mTOB inhibitor in the treatment of NSCLC with KARs 
gene mutation studied by Hai et al. [26]. Jhuraney et al. [27] 
found that Wee1 and PAXIP1 were commonly expressed 
in lung cancer,and had no relationship with the status of 
p53. When both were expressed at the same time, Wee1 
inhibitor combined with Cisplatin was effective.Sen et 
al. [28] a used PCR method to study and found that Wee1 
was significantly increased in small cell lung cancer cells 
compared with normal tissues and non-small cell lung 
cancer cell lines. Therefore, the mechanism and expres-
sion of Wee1 may be different in different types of lung 
cancer.
3.6 Wee1 and Lymphoma
Lymphoma is a malignant tumor originated from lym-
phohematopoietic system, which is a systemic disease. At 
present, the main treatment is chemotherapy, but lympho-
ma is heterogeneous, and the therapeutic effect is different 
greatly among different patients. Chemotherapy drugs 
such as cytarabine can cause DNA damage in B-cell lym-
phoma. The results showed that [29] in vivo and in vitro, 
Wee1 inhibitor combined with chemotherapy drugs was 
only effective in the treatment of B-cell lymphoma with 
G2 phase arrest. Diffuse large B-cell lymphoma (DLBCL) 
accounts for about 31% of all non Hodgkin's lymphoma. 
Although R-CHOP Regimen is more effective, there are 
still a lot of relapses or deaths.Studies have shown that 
Wee1 is more significantly expressed in DLBCL [30]. Wee1 
inhibitors combined with CDK1 inhibitors may improve 
the prognosis of patients with DLBCL [31], and Wee1 may 
become a target for the treatment of Diffuse Large B-cell 
Lymphoma. De Jong et al. [31] first proposed and verified 
that Wee1 inhibitor can enhance the anti-apoptotic depen-
dence of DLBCL, and the combination of Wee1 inhibitor 
and anti-apoptotic inhibitor has better efficacy. Chila et 
al. [33] demonstrated that CDK1 inhibitors and Wee1 in-
hibitors were more effective in Mantle Cell Lymphoma 
(MCL) than solid tumors and other lymphomas, but the 
high toxic side effects of dual-targeted agents remain to be 
addressed.
4. Wee1 Protein Kinase Inhibitors
Among tumor therapy drugs, targeted therapy drugs 
have been widely used in clinic. In recent years, Wee1 
protein kinase has attracted more and more attention in 
tumor cells with G1/S checkpoint deletion, and Wee1 
protein kinase plays a key role in G2/M phase, making 
Wee1 protein kinase become a potential target for clin-
ical treatment of tumors. Wee1 protein kinase inhibitor 
DOI: https://doi.org/10.30564/jor.v3i1.2851
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AZD1775, also known as MK1775, is an effective selec-
tive inhibitor of Wee1. AZD1775 can inhibit the activity 
of CDK1 by phosphorylating the Try15 residue of Wee1 
protein kinase, so that DNA damage repair can not be 
carried out smoothly, and cells can not produce substanc-
es entering M phase in G2 phase, which leads to apopto-
sis. Studies have proved that AZD1775 alone is effective 
in the treatment of tumors. Currently, the treatment 
methods for patients with ovarian cancer are not perfect. 
Zhang et al. [34] verified through animal experiments that 
Wee1 inhibitor MK1775 as a single preparation has an 
inhibitory effect on tumor cells of ovarian cancer, and 
Wee1 may become a potential target of ovarian cancer. 
Bi et al. [35] determined that the expression of Wee1 was 
increased in esophageal squamous cell carcinoma cells, 
and thus verified that AZD1775 alone could inhibit the 
proliferation and metastasis of cancer cells and induce 
their apoptosis. Jin et al. [36] found that Wee1 inhibitor 
AZD1775 can block mitosis in S phase in pancreatic 
cancer, and make the cells in this phase be inhibited and 
apoptosis, so as to achieve the effect of treating pancre-
atic cancer.
In recent years, Acute Lymphoblastic Leukemia (ALL) 
treatment drugs have made patients get very effective 
treatment effect, but tumor recurrence has become a prob-
lem perplexing patients and doctors. It has been proved 
that [37] AZD1775 combined with CHK1/CHK2 inhibitor 
can act in S phase to make DNA damage and achieve ther-
apeutic effect on patients with ALL. Junchenghu et al. [38] 
found that T-ALL was more dependent on G2/M phase in 
DNA damage due to the lack of G1/S phase, making Wee1 
a key therapeutic target. The experimental results showed 
that Wee1 was closely related to the glycolysis of cells, 
which verified that Wee1 inhibitor AZD1775 combined 
with GLS1 inhibitor CB-839 and BPTES had better effi-
cacy in the treatment of T-ALL than using the two drugs 
alone. According to Cody W. Lewis et al. [39], the presence 
of Myt1 in the cell cycle can phosphorylate the Thy14 site 
of CDK1, and also block the mitosis of cells, which can 
enhance the drug resistance of some tumors such as breast 
cancer to AZD1775. Therefore, the combined application 
of Wee1 inhibitor and Myt1 inhibitor in the treatment of 
some tumors may reduce the resistance of tumor cells to 
Wee1 inhibitor.
Other studies have demonstrated that Wee1 inhibitors 
will appear drug toxicity and drug resistance when used 
alone or in combination with other drugs to treat tumors, 
while Wee1 inhibitors will have better efficacy and fewer 
side effects when used continuously with other anti-tumor 
drugs. Yongfang et al. [40] showed that nausea, weight loss 
and other symptoms could occur when Wee1 inhibitors 
were combined with PARP inhibitors, while continuous 
use of the two drugs alone could not only kill tumor cells, 
but also improve toxicity in normal cells. There have 
also been studies [41] showing that sequential therapy with 
gemcitabine followed by Wee1 inhibitor can increase the 
number of tumor cell apoptosis more than alternating 
sequential therapy with gemcitabine followed by Wee1 
inhibitor or combination therapy of gemcitabine and Wee1 
inhibitor.
5. Summary
In this review, the role of Wee1 protein kinase in the 
cell cycle and the relationship between Wee1 protein ki-
nase and tumor were summarized, and the development 
of Wee1 protein kinase inhibitors in tumor therapy was 
summarized. Wee1 protein kinase inhibitors are poten-
tially targeted tumor therapy drugs. Currently, there are 
many researches on Wee1 inhibitors, but how to use 
Wee1 inhibitors to minimize the toxic and side effects 
of the treatment regimen is still controversial: Some 
scholars believe that single use is more effective than 
combined use; some scholars believe that combined use 
can reduce the side effects caused by Wee1 inhibitors, 
and combined use can maximize the efficacy; while 
others believe that neither single use nor combined use 
can bring the maximum benefit to patients as sequential 
therapy. As Wee1 protein kinase inhibitors are still in 
phase II clinical trials [42], how to keep the efficacy of the 
drug itself, and at the same time control the balance be-
tween Wee1 protein kinase inhibitors and other drugs or 
treatments to bring the greatest benefits to patients is the 
current research direction.
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